# Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

> **NCT05607329** · NA · RECRUITING · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 400 (estimated)

## Conditions studied

- Relapsed Ovarian Cancer

## Interventions

- **PROCEDURE:** Secondary cytoreduction
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05607329
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607329, "Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05607329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*